Screening for Fabry disease in people with kidney biopsy results
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a screening approach to find Fabry disease in adults whose kidney biopsy findings are unclear or suggest certain kidney patterns. If Fabry disease is missed, it can delay targeted treatment, so screening may help identify people who could benefit from earlier care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You are willing and able to sign consent to join the study.
- Your kidney problem fits at least one listed biopsy/presentation pattern (for example: unclear cause, specific types of scarring or “minimal lesions”).
- You have NOT been screened for Fabry disease before.
- You do NOT have certain kidney conditions like nephrotic syndrome or specific named biopsy diagnoses that would exclude you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the natural course of Fabry disease in the kidneys and how different kidney test results relate to each other. It may help doctors better understand kidney progression and treatment outcomes, including for people who have or have not had enzyme replacement therapy.
This study uses MRI scans to look at how Fabry disease affects the kidneys, including scarring, swelling, and oxygen levels. It may help researchers understand kidney problems better and find new ways to monitor the disease.
This study tests a new investigational drug called HM15421/GC1134A for people with Fabry disease. It aims to see if the drug is safe and tolerable, and to learn how well it works. You may be eligible if you have Fabry disease with symptoms, have not had treatment for at least 6 months, and your kidneys are functioning well.
This study checks whether certain heart-related blood tests and heart scans can help monitor people with Fabry disease. It may be useful for both people who have never received enzyme replacement therapy and those who have.
This study is a simple screening to check for early signs of chronic kidney disease. It aims to find kidney problems in people who are at higher risk due to age or other health conditions.
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
Hear when a new Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.